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Abstract 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in 
regulating lipoprotein metabolism by binding to low-density lipoprotein receptors 
(LDLRs), leading to their degradation. LDL cholesterol (LDL-C) lowering drugs that 
operate through the inhibition of PCSK9 are being pursued for the management of 
hypercholesterolemia and reducing its associated atherosclerotic cardiovascular disease 
(CVD) risk. Two PCSK9-blocking monoclonal antibodies (mAbs), alirocumab and 
evolocumab, were approved in 2015. However, the high costs of PCSK9 antibody drugs 
impede their prior authorization practices and reduce their long-term adherence. Given 
the potential of small-molecule drugs, the development of small-molecule PCSK9 
inhibitors has attracted considerable attention. This article provides an overview of the 
recent development of small-molecule PCSK9 inhibitors disclosed in the literature and 
patent applications, and different approaches that have been pursued to modulate the 
functional activity of PCSK9 using small molecules are described. Challenges and 
potential strategies in developing small-molecule PCSK9 inhibitors are also discussed.  
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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide despite 
advances in lifestyle and the available of various cardiovascular drugs.[1] 
Hypercholesterolemia has long been considered as an independent risk factor for CVD, 
and lowering low-density lipoprotein cholesterol (LDL-C) has been shown to reduce 
cardiovascular risk in clinical trials.[2] Several agents have been widely applied for 
reducing LDL-C levels in the treatment of hypercholesterolemia, including statins, 
ezetimibe, niacin, and bile acid sequestrates.[3] To date, 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins) have been widely regarded as 
the first line of pharmacological treatment for lowering LDL-C, reducing risk of 
primary and secondary cardiovascular events.[4] Despite the successful application of 
statins alone or in combination with other lipid-lowering drugs, residual risk persists in 
a large portion of statin-treated patients (~25%) who fail to attain desirable LDL-C 
levels with the maximally tolerated statin therapy[5] or are intolerant to statins owing 
to various side effects such as muscle symptoms, headache, sleep disorder, rash, 
arthritis, etc.[6] Thus, safer and more effective nonstatin therapies for the treatment of 
dyslipidemia to reduce cardiovascular risk are needed.  
PCSK9 is a recently identified but well-validated novel drug target that lowers LDL-
C levels for hypercholesterolemia treatment.[7] This protein plays an important role in 
regulating the degradation of hepatic low-density lipoprotein receptors (LDLRs), 
thereby increasing circulating LDL-C levels.[8] Various therapies have been designed 
to inhibit PCSK9 and consequently inhibit LDLR degradation.[9] In 2015, two fully 
human monoclonal antibodies (mAbs), alirocumab[10] and evolocumab,[11] were 
approved as PCSK9 inhibitors. They are efficacious, well tolerated, and have no 
obvious side effects.[12, 13] Recent clinical data of evolocumab have shown a 
reduction in cardiovascular events by 15% after a median treatment of 2.2 years, 
confirming the clinical benefit of PCSK9 inhibition as a drug target.[11]  
The most studied and clinically approved approach to inhibit PCSK9 is the use of 
mAbs, and comprehensive reviews have summarized the development process, safety 
and tolerability of anti-PCSK9 antibodies.[14-17] Given the intravenous administration 
and high cost of mAbs (>$14,500 per year), the appeal of small-molecule inhibitors of 
PCSK9 with lower cost and ease of administration is clear.[18] However, targeting 
PCSK9 with small-molecule approaches has proven a great challenge due to the lack 
of druggable pockets on PCSK9. Nevertheless, there has been a rapid increase in reports 
about small-molecule PCSK9 inhibitors in recent years.[19] Here, we'd like to provide 
a comprehensive overview of studies on the small molecules targeting PCSK9 in 
scientific literature and patent applications. We will first give an overview of the 
biogenesis, structure and physiological role of PCSK9 in lipid metabolism. Then, 
current strategies reported in the literature based on reducing the synthesis of PCSK9 
or disturbing the binding of PCSK9 to the LDLR will be introduced in detail; in addition, 
several natural products modulating the expression, activity or functionality of PCSK9 
will also be described. All international patent applications (2010-2018) protecting 
novel small molecules targeting PCSK9 will be covered. Finally, novel strategies that 
have the potential to assist the further development of small-molecule PCSK9 inhibitors 
and future challenges will be discussed. 
 
2. Background 
2.1. Biogenesis and structure of PCSK9 
The human PCSK9 gene, initially called 'neural apoptosis-regulated convertase 1' 
(NARC1), was discovered by Seidah et al., who reported the identification of the ninth 
member of the mammalian proprotein convertase family located on chromosome 
1p32.3.[20, 21] The PCSK9 gene on the short arm of chromosome 1 is 25 kb long and 
contains 12 exons and 11 introns (Figure 1a). PCSK9 encodes an inactive glycoprotein 
(pre-PCSK9) with 692 amino acids comprising four major components: a signal 
sequence (1-30) and N-terminal prodomain (31-152), followed by a subtilisin-like 
catalytic domain (153-425) and a C-terminal domain (426-692, also called the V 
domain).[22] Once the signal peptide is cleaved from pre-PCSK9 in the endoplasmic 
reticulum, pro-PCSK9 (31-692) is formed and then converted to mature secretory 
PCSK9 through autocatalytic cleavage of the prodomain between Gln152 and 
Ser153[23] in the Golgi apparatus (Figure 1b).[24] However, unlike the other 
proprotein convertases, the cleaved prodomain of PCSK9 remains tightly associated 
with the catalytic domain, where it inhibits further catalytic activity.[25]  
PCSK9 binds to LDLRs on the cell surface, leading to their degradation. The binding 
site of PCSK9 localizes to the EGF(A) (epidermal growth factor A) domain of the 
LDLR (Figure 1c). The binding surface of PCSK9 is formed primarily by residues 367-
381, constructing an exposed, slightly convex ~500 Å2 region. The key interactions of 
PCSK9 with EGF(A) are made by an antiparallel β-sheet formed between residues 377-
379 of PCSK9 and 308-310 of EGF(A). In addition, Arg194 and Asp238 of PCSK9 are 
also important for the binding. Other residues of PCSK9 such as Phe379, Ile369, and 
Cys378 also contribute to this interface (Figure 1d).[26] 
 
 
Figure 1. Gene location (human) and structure of PCSK9. (a) Gene location of PCSK9. 
(b) Structure of PCSK9, with the pro-domain (violet), the catalytic domain (forest), and 
the V-domain (pale yellow). (c) The binding surface of PCSK9 with EGF-A. The 
surface of PCSK9 buried upon binding to EGF-A is colored according to element type: 
carbon, warmpink; nitrogen, blue; oxygen, red; sulfur, limon. EGF-A is represented as 
a marine cartoon model. (d) Key interactions between PCSK9 (magenta) and EGF-A 
(Green). 
 
2.2. Physiological role of PCSK9 
In 2003, novel gain-of-function (GOF) mutations (S127R, F216L) in the PCSK9 gene 
were identified by Abifadel et al. in two French families with autosomal dominant 
hypercholesterolemia.[27] By contrast, loss-of-function (LOF) mutations have the 
opposite effect and result in hypocholesterolemia. Since then, PCSK9 has emerged as 
a novel therapeutic target for the treatment of dyslipidemia. Several lines of evidence 
have demonstrate an LDL-C lowering mechanism in which PCSK9 lowers the amount 
of hepatic LDLR proteins and thus compromises the liver’s ability to remove LDL-C 
from circulation.[28] As shown in Figure 2, under normal physiological conditions, 
circulating LDL is bonded to LDLRs at the hepatocyte surface and then internalized 
into hepatocytes through clathrin-mediated endocytosis as a receptor-ligand complex. 
The low pH in the endosome leads to dissociation of the LDL from its receptor, and the 
LDL is degraded in the lysosome, while the LDLR is recycled to the cell surface.[29, 
30] However, in the presence of PCSK9 at the hepatocyte surface, the catalytic domain 
of secreted PCSK9 associates with the EGF(A) domain of the LDLR, and the 
PCSK9/LDLR complex is internalized into hepatocytes.[31] The low pH of the 
endosome enhances the affinity of PCSK9 for the LDLR, preventing the receptor from 
being recycled to the cell surface. Instead, the complex is directed to the lysosome, 
where LDLR is concomitantly degraded along with the complexed LDL particle.[32, 
33]  
 
2.3. Approaches to PCSK9 inhibition 
After the identification of LOF and GOF mutations of PCSK9 in human, great efforts 
have been made to discover PCSK9 inhibitors that act as therapeutic agents to lower 
LDL-C.[34, 35] At least nine different modalities targeting PCSK9 have arisen, 
including mAbs, peptidomimetics, antisense oligonucleotides, small interfering RNA 
(siRNA), vaccines, CRISPR (clustered regularly interspaced short palindromic repeats) 
therapeutics, antibody mimetics (including adnectin and anticalin), and small 
molecules.[36] The potential advantages and disadvantages of these modalities as well 
as the clinical studies of their effectiveness are summarized in Table 1.   
In terms of mechanism, the success of these modalities is roughly attributed in this 
review to three strategies that target PCSK9 (Figure 2). Strategy 1 is to directly or 
indirectly prevent binding of PCSK9 to the LDLR on the cell surface with an antibody, 
a peptide, or a small molecule. Strategy 2 is to interfere with the maturation and 
secretion processing or the biological function of PCSK9. Strategy 3 is to develop 
inhibitors of PCSK9 synthesis and expression at the mRNA or protein levels. These 
three strategies have been successfully applied to develop small-molecule PCSK9 
inhibitors in recent years. Although only one PCSK9 small molecule is currently active 
in clinical trials (see section 3.6.2), there has been a steady increase in available data on 
small-molecule PCSK9 inhibitors in recent years. This review will provide an updated 
view of small-molecule PCSK9 inhibitors reported in scientific journals and patent 
applications.  
 
Figure 2. PCSK9 is produced mainly by the liver and is secreted into the bloodstream. 
Upon binding to liver LDLRs, the entire PCSK9/LDLR complex is endocytosed and 
subsequently directed to lysosomes for degradation. Strategies targeting the synthesis, 
processing, and binding of PCSK9 could be adopted to develop PCSK9 inhibitors.   
 
Table 1 
Pharmaceutical approaches targeting PCSK9 
Approach Mode of action Advantages Disadvantages Agent[Ref] Stage Company 
Monoclonal 
antibodies 
(mAbs) 
Blocking 
interaction with 
LDLR or 
neutralizing 
PCSK9 activity. 
Efficient and safe 
High specificity 
Low toxicity 
Short shelf-life 
compared with 
siRNA  
High cost 
Parenteral 
administration 
Evolocumab [10] 
Alirocumab [11] 
Bococizumab[37] 
 
LY-3015014[38, 39] 
RG-7652[40, 41] 
Approved-2015 
Approved-2015 
Phrase III 
(Discontinued) 
Phase II 
Phase II 
Amgen 
Sanofi 
Pfizer 
 
Lilly 
Genentech/Ro
che 
Small 
Peptides 
Blocking 
interaction with 
LDLR 
Cheap Instability in plasma 
Parenteral 
administration 
Pep2-8[42] Preclinical Genentech 
Antisense 
oligonucleo
tides  
Silence mRNA 
Leading to mRNA 
degradation 
High specificity High production 
costs 
Parenteral 
administration 
SPC5001[43] 
 
BMS-844421[44] 
 
Civi-007[45] 
Phase I 
(Discontinued) 
Phase I 
(Discontinued) 
Phase I 
Roche 
 
BMS 
 
Roche 
  
siRNA Target PCSK9 
mRNA and arrest 
translation 
Long-acting  
Safe 
Less-frequent 
dosing 
Parenteral 
administration 
Inclisiran (ALN-
60212) [46, 47] 
Phase III Alnylam/The 
Medicines 
Company  
Adnectin Blocking 
interaction with 
LDL-R 
High binding 
affinity 
Relative cheaper 
production cost 
Short plasma half-
life 
BMS-962476[48] Phase I BMS 
Anticalin Blocking 
interaction with 
LDL-R 
Antibody mimetic 
but smaller than 
mAbs, 
Mass production 
at low cost  
Design and 
screening 
DS-9001a[49] Phase I 
(Discontinued) 
 
Daiichi 
Sankyo/Pieris 
Pharmaceutica
ls 
Vaccine Immunization 
against the body’s 
own PCSK9 to 
produce 
autoantibodies 
High immune 
response against 
PCSK9 without 
side effects 
Long-term effects 
Possible 
irreversibility 
Autoimmune 
response 
AT04A& AT06A[50] Phase I 
Phase I 
AFFiRis 
AFFiRis 
CRISPR Genome editing 
disrupting PCSK9 
gene 
Permanent 
reduction in LDL-
C levels 
Potential off-target 
mutagenesis 
Academic project and 
AstraZeneca[51-55] 
Preclinical AstraZeneca 
Small 
molecules 
As detailed below Cheap 
Oral 
administration 
High likelihood of 
off-target 
As detailed below Preclinical As detailed 
below 
 
 
3. Small-molecule PCSK9 inhibitors reported in scientific journals 
3.1. Blocking the ribosome: from R-IMPP to PF-06815345  
In the search for small molecules that inhibit PCSK9 production, researchers from 
Pfizer have presented a fascinating work determining PCSK9 secretion through high-
throughput screening (HTS).[56] R-IMPP (1, PF-00932239, Figure 3) was identified as 
a new anti-PCSK9 small lead through a phenotypic screen from a screening set of 2.55 
million compounds. This process was challenging based on the following threshold 
values: for ProLabel tag chemiluminescent assays, IC50 < 10 µM; for secreted alkaline 
phosphatase nonspecific secretion assays, IC50 > 10 µM; and for ATP cytotoxicity 
assays, IC50 > 10 µM. Finally, R-IMPP was identified as a weak PCSK9 
antisecretagogue with an IC50 value of 4.8 µM in a CHO-K1 cell line overexpressing 
recombinant ProLabel-tagged PCSK9 and an IC50 of 2 µM in native cell lines.[57] The 
pharmacokinetic properties of PF-00932239 were not satisfactory, and structural 
changes were made to two regions of hit compound (2) to improve its pharmacokinetic 
properties and potency, resulting compound PF-06446846 (3).[58] PF-06446846 
inhibited the secretion of PCSK9 with an IC50 of 0.3 μM in Huh7 cells. The mechanism 
of action of this compound was shown to be new, as it demonstrated the ability to 
selectively bind to human (but not Escherichia coli) 80S ribosomal complex, causing 
the ribosome to stall on mRNA near the position predicted to generate a 35 amino acid 
peptide.[59] This work generated fascinating new insight into the basic biology of 
ribosomal processing.[60, 61]  
Although PF-06446846 (3) exhibits a high degree of specificity for inhibiting the 
expression of PCSK9, the narrow margin between PCSK9-lowering and hematopoietic 
effects prevents the clinical development of PF-06446846. Thus, efforts to achieve 
better safety by narrowing the tissue distribution of these compounds was continued 
using a hepatic targeting approach.[62] An acidic/anionic functionality was introduced 
into benzamide (4, 5) to facilitate liver-targeted delivery of these PCSK9 inhibitors 
according to previous structure-activity relationships (SARs).[63, 64] Unfortunately, 
these zwitterions lacked anti-PCSK9 pharmacology in cell-based assays due to their 
poor permeability. Thus, an exquisite ester, which is labile to carboxylesterase 1 (CES1) 
in the liver, was added to compounds 4 and 5 to make prodrugs.[65] Metabolism of 
these prodrugs in hepatocytes revealed the active zwitterion that was retained by its 
poor passive permeability. Finally, compound 6 (PF-06815345) was selected as a 
candidate, as it was relatively well tolerated in 28 day preclinical toxicity studies in rats 
and monkeys. Further studies are needed to understand the potential of this therapeutic 
modality and the liver targeting approach. 
In parallel, efforts to transform compound 3 into molecules with high systemic 
bioavailability and an improved balance of safety and efficacy suitable for further 
development were also explored.[66] It was found that subtle structural changes around 
benzamide and N-triazolopyridine moieties of 3 yielded significant changes in 
pharmacology and off-target toxicity. Synthetic SAR evaluations were performed 
abound these two regions to establish a correlation between substituent and toxicology 
to seek out the analogues of interest, and resulted in identification of compounds 7 and 
8 with similar potencies and improved in vivo toxicology profiles. The improved safety 
profile may be related to diminish binding of these compounds to nontranslating 
ribosomes, but great efforts should be made to understand the translational selectivity.     
The strategy adopted by Pfizer was extremely innovative, as translational inhibitors 
were generally confined to antibacterials;[67] however, Pfizer demonstrated that small 
molecules can specifically inhibit the translation of a single disease-associated protein 
by stalling the ribosome chain, truly opening new paradigms to overcoming 
‘undruggable’ proteins. But whether this strategy could be applied to other target to 
find highly selective translational inhibitors remains unclear.  
 
Figure 3. Strategies adopted by Pfizer for the development of PF-06815345 and 
compounds 7 and 8. 
 
3.2. Heparan sulfate mimetics 
It is well known that PCKS9 interacts with the LDLR, causing the receptor to 
internalize, and consequently reduces the clearance of LDL. However, the 
PCSK9/LDLR binding constant is in the range of 170-628 nM, while the PCSK9 
plasma concentration is approximately 6 nM.[68] Thus, as it is unlikely that the PCSK9 
in the circulating system binds directly at normal physiological concentrations, some 
co-receptor may be involved in the interaction between PCSK9 and LDLR. Recently, 
Gustafsen and colleagues proposed the provocative concept that heparin sulfate 
proteoglycans (HSPGs) participate as a receptor for PCSK9 in the liver and facilitate 
the clustering of PCSK9 to LDLR.[69] The authors proved that HSPGs on the 
hepatocyte surface capture PCSK9 and present it to the LDLR, ensuring the optimal 
conditions for PCSK9/LDLR complex formation. HSPGs participate in the regulation 
of a wide range of physiological and pathological phenomena, including developmental 
processes, angiogenesis, blood coagulation, and tumor metastasis.[70] Heparan sulfate 
(HS) is a linear polysaccharide chain composed of repeating linked pyrosulfuric acid 
and 2-amino-2-deoxy glucopyranose residues, and two or three HS chains are 
covalently attached to serine residues of the core proteins to form HSPGs. The HS-
binding site on PCSK9 is located in the prodomain of PCSK9 and formed by surface-
exposed basic residues interacting with trisulfated heparan sulfate disaccharide repeats. 
Heparin or heparan sulfate mimetics, interrupting the HS/PCSK9 interaction directly 
through binding to the HS-binding surface on PCSK9, would reduce PCSK9 activity 
and to be developed as PCSK9 inhibitors.[69] 
Several molecules mimicking the structure of heparin, including dextran sulfate (9), 
pentosan sulfate (10), suramin (11) and the phosphorothioate oligonucleotide S-dC-36 
(12), were screened for their abilities to inhibit PCSK9 and increase LDLR in HepG2 
cells. S-dC-36 (12) was the most potent HS mimetic binding PCSK9 with a KD of 4.8 
μM. Interestingly, five clinical trials for anticoagulation with low-dose heparin at 
subtherapeutic amounts all reported marked reductions in cardiac events, although the 
mechanism for this has remained unclear.[71-75] The results from Gustafsen and 
colleagues may partly explain this phenomenon. In addition, chitosan oligosaccharides, 
linear polymers of N-acetyl-D-glucosamine and deacetylated glucosamine, were 
recently reported to enhance the level of lipid droplets via downregulation of PCSK9 
gene expression, suggesting saccharide might be a potential source of PCSK9 
inhibitors.[76] It should be noted that the binding affinities of these heparan sulfate 
mimetics to PCSK9 were not high, further structural modifications with these 
molecules as leading compounds to find potent small-molecule PCSK9 inhibitors might 
be an effective method. 
 Figure 4. Heparan sulfate mimetics as PCSK9 inhibitors. 
 
3.3. CB_36 from in silico screening 
Although the motif of PCSK9 that binds to the EGF(A) domain of LDLR has been well 
characterized, the application of this interaction for the in silico virtual design of small 
molecules is a great challenge due to the lack of appropriate binding pocket. Min and 
co-workers tried to develop small-molecule inhibitors using a in silico virtual screening 
approach based on the PCSK9/LDLR interaction.[77] PCSK9 amino acids from 367 to 
381, located where the EGF(A) domain of the LDLR binds, were extracted and assigned 
to be the target of the inhibitors. The PCSK9 protein structure from Protein Data Bank 
(PDB) was pretreated by removing the EGF(A) domain and water molecules, followed 
by the supplementation of hydrogen atoms. Subsequently, GOLD software version 
4.0.1 was used to calculate the docking scores of ~450,000 chemicals from the 
ChemBridge Express database. The top 100 chemicals with the highest docking scores 
were selected to evaluate their in vitro activities using a PCSK9/LDLR binding assay, 
immunoblot analysis, and an LDL-C uptake assay. Most of the potent compounds (13) 
have fragments that structurally resemble the plasticizer bisphenol A and were 
protected in WO 2016/108572 A2.[78] The most potent chemical, CB_36 (14), was 
validated as an inhibitor perturbing the linkage between PCSK9 and LDLR in a dose-
dependent manner. However, whether this compound directly binds to PCSK9 and 
exerts its effects mediated by PCSK9 in a specific-manner remains to be proven. 
 
Figure 5. CB_36 from in silico screening. 
 
3.4. Imidazole-based minimalist peptidomimetic 
Disrupting the protein-protein interaction (PPI) between PCSK9 and LDLR is an 
effective strategy, and several peptides have been developed accordingly.[42, 79] 
However, the search for alternatives to peptides, such as secondary-structure mimics of 
the main recognition motifs, that can be induced to fold into protein-like bioactive 
conformations that include ɑ-helices, β-turns and β-strands, has received less 
attention.[80] The X-ray crystal structure of PCSK9/LDLR clearly showed a β-strand-
mediated interaction formed by the residues C378-F379-V380-S381 of PCSK9 and 
V328-C329-N330-D331 of LDLR.[81] This evidence suggests that a small β-strand 
peptidomimetic resembling these native β-strand sequences (15), can function as a 
PCSK9 inhibitor through interfering with the PCSK9/LDLR reciprocal interaction.  
Stucchi and co-workers reported a multicomponent synthesis of a novel imidazole-
based peptidomimetic (17), that mimicked the conformation of a β-strand in terms of 
both the side chain orientation and the interstrand H-bond donating capability (Figure 
6).[82] This peptidomimetic is more like a small molecule than a peptide as its molecule 
weight is 395 Da. Remarkably, the in vitro PCSK9-LDLR binding assay showed that 
this compound induces a concentration-dependent inhibition of the PPI and that the IC50 
value is 11.2±0.2 μM. Reducing the number of imidazole rings from 4 to 3 caused a 
significant decrease in the IC50, suggesting the importance of the tetraimidazole 
scaffold. However, a fluorescent-LDL uptake experiment showed that this compound 
increased the LDL uptake with an EC50 of 6.04 μM, which was lower than the IC50 for 
the binding affinity of this compound to PCSK9.  
Although β-strand peptidomimetics have been successfully applied as enzyme 
inhibitors,[83] this report is the first of an imidazole-based minimalist β-strand mimic 
as a PCSK9 inhibitor. This β-strand mimic paves the way for the future development 
of a new class of PCSK9 inhibitors. Future development of peptidomimetics might be 
focused on the number of imidazoles and the substitutions of imidazoles and N-Me 
groups to mimic the LDLR β-strand more strictly to improve the specificity.  
 
 
Figure 6. Small β-strand peptidomimetics as PCSK9 inhibitors.  
 
3.5. Discovery of semirigid scaffold using Exploring Key Orientations 
A recent story about peptidomimetics comes from Burgess and co-workers.[84] They 
hypothesized that a set of privileged conformational mimics of semirigid scaffolds 
bearing amino acid side-chains could be compared with PPI-interface regions to 
facilitate the development of peptidomimetics to perturb the PPI. They call this concept 
Exploring Key Orientations (EKOs), and developed a data mining algorithm to find 
such chemotypes that match PPI interfaces and, thereby perturb the interface.[85, 86] 
In 2018, several candidate chemotypes were conceived and screened as PCSK9 
inhibitors using the EKO approach by the Burgess group. They found that molecule 18 
was superimposed on LDLR in the PCSK9/LDLR complex in several ways. 
Specifically, five groups of interface side-chains of LDLR in the PCSK9/LDLR crystal 
structure (Asp299, Leu298, and Asp301; Cys297, Asn301, and Asp299; Leu298, Asp299, and 
Asn301; Val307, Cys308, and Leu318; Asn309, Cys308, and Leu318), might be overlaid by 
compound 18. Interestingly, Asp299, Leu318, and Asn309 were implied as “hot spots” in 
LDLR side-chains implicated in the PCSK9/LDLR interface based on crystallographic 
studies.[28] Subsequently, the R1-R3 side chains in compound 18 were replaced with 
the natural side chains from the LDLR protein, and a series of compounds were 
prepared and tested using a time-resolved fluorescence resonant energy transfer (TR-
FRET) assay. However, inconclusive results compelled the authors to improve the 
affinity of these compounds by appending additional pharmacophores using an iterative 
docking and energy minimization procedure. Consequently, structures 19 were 
conceived by including an Arg at the C-terminus of structure of 18 to fill the negative 
pocket in PCSK9. A solid-phase synthesis method was applied to install the R1-R4 side 
chains of chemotype 19, and 15 compounds were finally prepared for screening. Three 
hit compounds exhibited promising dissociation constants for PCSK9 binding in 
surface plasmon resonance (SPR) analyses: 20 (LDLL-1dlnr, Kd 24.8±9.1 μM), 21 
(DLLD-1nclk, Kd 41.2±17.5 μM), and 22 (LDLL-1dl(CN)r, Kd 35.8±11.4 μM). In 
addition, LDLL-1dlnr (20) was modified with a photoaffinity label and found to form 
a covalent conjugate with PCSK9 upon photolysis. It should be noted, as complex 
unnatural amino acids, further modifications on these amino acid side-chains to regulate 
the lipid-water partition coefficient and improve bioavailability are need.    
 Figure 7. Discovery of semirigid scaffold using Exploring Key Orientations strategy. 
 
3.6. Natural products 
Despite of the high efficacy of approved PCSK9 antibody drugs, a few studies of 
developing natural products as lipid-lowering agents have been reported in recent 
years.[87, 88] Some of these natural products have been reported to hinder the function 
of PCSK9 directly or indirectly.[89, 90] Berberine, corydaline, curcumin, lignans, 
polydatin, flavones, etc. have been widely studied and identified to lower the expression 
of PCSK9. The mechanism studies of these natural products showed that most of these 
compounds alter PCSK9 status through modulating either PCSK9 expression or mature 
protein secretion. However, more mechanistic investigations of these natural products 
are required, and these studies would facilitate reveling the signaling pathways 
associated with PCSK9. In the following section, we will review natural products with 
potential PCSK9 inhibitory effects.  
 
3.6.1. Berberine 
Berberine (23, BBR, Figure 8) is an isoquinoline plant alkaloid isolated from Berberis, 
such as Rhizoma coptidis, Scutellaria baicalensis and Phellodendron amurense.[91] In 
recent years, increasing evidence has suggested an ability of BBR to improve lipid 
metabolism, and several clinical studies have also tested the efficacy of BBR in 
humans[92, 93] and implied that BBR administration might be a potential therapeutic 
approach for hypercholesterolemia. Studies have shown that BBR significantly 
increased LDLR expression through a posttranscriptional mechanism that stabilizes the 
LDLR mRNA[94] and that it reduced the expression and secretion of PCSK9.[95] 
However, the detailed mechanism by which BBR affects PCSK9 expression remains 
unclear. Cameron and co-workers suggested that BBR decreased PCSK9 mRNA and 
protein levels in a time- and dose-dependent manner and that this effect was not due to 
increased degradation of PCSK9 mRNA but most likely to decreased transcription of 
PCSK9.[95] Subsequently, sterol regulatory element binding protein-2 (SREBP-2) and 
hepatocyte nuclear factor 1α (HNF-1α) were identified to have roles in the BBR-
mediated suppression of PCSK9 transcription.[96] A highly conserved HNF-1 binding 
site located between the SRE and Sp1 sites was identified as a critical cis-regulatory 
sequence of the PCSK9 promoter.[96]  
 
Figure 8. Structures of some natural products with potential PCSK9 inhibitory effects.  
 
3.6.2. CVI-LM001 from corydaline 
Corydaline (41, Figure 9) is an isoquinoline alkaloid with antiacetylcholinesterase, 
antiallergic and antinociceptive activities isolated from traditional Chinese herb 
Corydalis yanhusuo.[97, 98] Recent studies showed that corydaline also possesses 
several other pharmacological activities, including antienterovirus,[99] antiplatele,[100] 
and antifungal activities.[101] The lipid-lowering effect of corydaline or its derivatives 
have rarely been reported. Nevertheless, in 2008, CVI Pharmaceuticals (CVI) disclosed 
the hypocholesterolemic effects of compounds or derivatives from Corydalis. In their 
disclosed patent, a series of isoquinolinyl-containing alkaloids, such as corydaline, 
corlumidin, corypalmine, bicuculline, tetrahydropalmatine, egenine and their 
derivatives were protected as hypocholesterolemic agents.[102, 103] The compounds 
disclosed there also lower total cholesterol (TC), LDL-C, and triglycerides. CVI-
LM001 (42), the fluorobenzenesulfonate derivative of corydaline, was selected for 
preclinical studies, and the results confirmed the hypolipidemic effect of CVI-LM001 
in hypercholesterolemic animal models, including a hamster model of hyperlipidemia 
and a diet-induced hyperlipidemia model in rabbits. The mechanism studies 
demonstrated that increases in hepatic LDLR expression, inhibition of PCSK9 
expression and activation of AMP-activated protein kinase (AMPK) might explain the 
lipid-lowering efficacy of CVI-LM001. In February 2016, CVI initiated two small 
phase I clinical trials in China to estimate the preliminary pharmacokinetic and safety 
profiles of CVI-LM001.[104] It should be noted that although CVI-LM001 is a 
derivative of a natural product, it is the world’s first orally administered small-molecule 
PCSK9 inhibitor in clinical studies. Recently, Liu and other inventors from the 
Shanghai Institute of Materia Medica described that phenyl [a]indole[2,3-g]quinolizine 
compounds can be used for treating diseases related to PCSK9 (WO 2017/167202 
A1)[105]. The disclosed compounds possess a quinolizine skeleton, which is similar to 
natural product corydaline (41), typical compound C97 (43) is described in Figure 9. 
 
Figure 9. Development of CVI-LM001 from corydaline and related analogues reported 
in patent WO 2017/167202 A1. 
 
3.6.3. Curcumin 
Curcumin (24, Figure 8) is a polyphenolic diarylheptanoid found in turmeric, a spice 
derived from the rhizomes of the plant Curcuma longa Linn.[106] Mounting evidence 
has demonstrated its positive effects in the treatment and prevention of cancer, 
Alzheimer’s disease, multiple sclerosis, etc.[107] The lipid-lowering effect of curcumin 
has been witnessed in several experimental and clinical studies.[108, 109] In 2014, Tai 
and co-workers showed that curcumin increased LDLR expression through the 
suppression of PCSK9 expression and that HNF-1α is the curcumin-responsive element 
of the PCSK9 regulator.[110] Recently, the inhibitory effect of curcumin on PCSK9 in 
rat liver cirrhosis was also evaluated, and the results showed that curcumin protected 
against intestinal origin endotoxemia by inhibiting PCSK9 to promote LDLR 
expression.[110] However, the global pharmacological effects of curcumin may 
impend the further development of curcumin as PCSK9 expression inhibitor due to its 
multiple molecular targets. It should be noted that curcumin shows positive results in 
most drug screening assays and is regarded as a pan-assay interference compound, 
which may lead to misinterpretations of results. Some researchers even conclude that 
"curcumin is an unstable, reactive, nonbioavailable compound and, therefore, a highly 
improbable lead".[111] 
 
3.6.4. Lignans 
The lignans are a large group of polyphenols found in many vascular plants and have 
relevant health properties, including anticarcinogenic, anti-inflammatory and 
antioxidant activity.[112] Recently, a bioactivity-guided isolation of the fruits of S. 
chinensis using a PCSK9 mRNA expression screening assay identified the hexane-
soluble extract as the active part. It total, 30 compounds were characterized, and four 
compounds potently inhibited PCSK9 mRNA expression: a tetrahydrofuran-type lignan 
(manglisin E (25), with an IC50 value of 3.15 μM), and three dibenzocyclooctadiene-
type lignans (schisandrin C (26), schinlignan D (27), and schisandrol B (28), with IC50 
values of 3.85, 0.36, and 1.10 μM, respectively) (Figure 8).[113]  
 
3.6.5. Moracin C 
Several nutritional compounds (NUTs) have been used against hypercholesterolemina 
as an alternative to pharmacological therapy. One innovative NUT combination 
(LopiGLIK®), containing red yeast rice (monacolin K 3.3 mg), berberine (531.25 mg) 
and leaf extract of Morus alba (200 mg), has exhibited beneficial effects in reducing 
the plasma levels of the TC and LDL-C by 9.8% and 12.6%, respectively.[114] The 
hypolipidemic activity and mechanism of berberine have been studied extensively; 
however, the chemical constituents and mechanism responsible for the hypolipidemic 
activity of Morus alba extracts still need deep research.[115] Recently, a study from 
Pel and co-workers showed that moracin C (29) inhibited PCSK9 mRNA expression 
and thereby decreased the degradation of LDLR, which could be the active component 
responsible for the hypolipidemic effect of Morus alba extracts.[116] A PCSK9 mRNA 
expression monitoring assay in HepG2 cells first isolated and identified 15 compounds 
from a chloroform-soluble extract of dried Morus alba fruits, and subsequent assays 
showed that moracin C inhibited PCSK9 mRNA expression with an IC50 value of 16.8 
μM in HepG2 cells.   
 
3.6.6. Polydatin  
Resveratrol is a biologically active stilbenoid present in various plant species and 
known to have numerous health-promoting effects. Since polydatin (30) is a glycoside 
precursor of resveratrol (resveratrol-3-O-β-mono-D-glucoside), its regulation on lipid 
metabolism has attracted considerable attention.[117] To explore the possible 
mechanism by which polydatin acts on lipid metabolism, Wang et al. evaluated the role 
of polydatin in insulin-resistant HepG2 cells and db/db mice. The results showed that 
polydatin not only upregulated the protein level of LDLR but also inhibited both the 
expression of PCSK9 and its interaction with LDLR in insulin-resistant HepG2 cells. 
In addition, polydatin significantly enhanced glucokinase and LDLR protein levels and 
inhibited PCSK9 expression in the liver.[118]  
 
3.6.7. Tanshinone IIA 
Tanshinone IIA (31) is a phenanthrene-quinone constituent of the Chinese medicinal 
herb Danshen (Salvia miltiorrhiza), which has been used clinically in Asia for the 
prevention and treatment of CVD.[119] A hypocholesterolemic effect of tanshinone 
IIA was reported recently by Chen and co-workers.[120] They demonstrated that 
tanshinone IIA significantly increased the amount of LDLR and LDL uptake activity 
in HepG2 cells via posttranscriptional regulation. The expression of PCSK9 mRNA 
and mature protein was also inhibited by tanshinone IIA in HepG2 cells. Further 
mechanism studies showed that tanshinone IIA increased the nuclear forkhead box O3a 
(FoxO3a) level, enhanced FoxO3a/PCSK9 promoter complex formation and decreased 
the PCSK9 promoter-binding ability of HNF-1α, resulting in the suppression of PCSK9 
gene expression. These results demonstrate that tanshinone IIA modulates cholesterol 
via downregulation of PCSK9 expression in hepatic cells. However, Jia et al. showed 
the conflicting result that tanshinone IIA promoted PCSK expression in the livers of 
hyperlipidemic rats, by upregulating the mRNA expression levels of SREBP-2 and 
PCSK9.[121] Further studies might be required to investigate the underlying molecular 
mechanisms of tanshinone IIA and make a definitive conclusion.  
 
3.6.8. Aromatic compounds from Sparassis crispa 
Sparassis crispa (Wulf.) is a species of fungus in the genus Sparassis. It is a medicinal 
mushroom whose fruiting bodies possess various bioactive substances such as β-glucan, 
benzoate derivatives, maleic acids, and sesquiterpenoids.[122] Recently, fourteen 
compounds were isolated by Bang and co-workers from the EtOAc-soluble extracts of 
the fruiting bodies of S. crispa.[123] Among them, four compounds exhibited potent 
inhibition of PCSK9 mRNA expression: sparoside A (32, IC50 = 20.07 μM), 
hanabiratakelide A (33, IC50 = 7.18 μM), 5α,6α-epoxy-(22E,24R)-ergosta-8(14),22-
diene-3β,7β-diol (34, IC50 = 8.23 μM), and adenosine (35, IC50 = 18.46 μM). 
 
3.6.9. Flavonoids and flavanones 
Flavonoids and flavanones have been reported to down-regulated the PCSK9 gene 
expression. A methanolic extract of S. baicalensis was recently found to inhibit PCSK9 
mRNA expression by Chin and co-workers. Nine compounds were isolated and 
compounds 36 (skullcapflavone II) and 37 (3,7,2’-trihydroxy-5-methoxy-flavanone) 
exhibited inhibitory activity at 20 μM (42.4% and 84.4%, respectively). Further studies 
showed that the expression of SREBP-1 mRNA was downregulated by compounds 36 
and 37, indicating that inhibition of PCSK9 mRNA was mediated by SREBP-1.[124] 
Quercetin is one of the most abundant dietary flavonoids with an average daily 
consumption of 25-50 mgs.[125] Quercetin is the aglycone form of many flavonoid 
glycosides, such as quercitrin, guaijaverin, hyperoside, and isoquercitin, and quercetin-
3-glucoside (Q3G, 38) is the quercetin 3-O-β-D-glucoside. This flavonoid glycoside 
has been shown to reduce diet-induced hyperlipidemia and atherosclerosis in mice.[126] 
Mbikay et al. examined the effects of micromolar concentrations of Q3G on LDLR and 
PCSK9 expression using human Huh7 hepatocytes, and the results showed that Q3G 
decreased the mRNA expression of PCSK9 by 20-30% while increasing the mRNA 
and protein expression of LDLR by 60 and 300-400%, respectively. Treatment with 
Q3G significantly reduced PCSK9 secretion, thereby causing its intracellular 
accumulation, and this PCSK9 retention might be partly due to induced sortilin 
deficiency.[127] Pinostrobin (39) was also found to inhibit the PCSK9 promoter 
activity and the suppression of PCSK9 mRNA expression in HepG2 cells through the 
up-regulation of the FoxO3a level.[128] Very recently, naringin (40), a flavanone-7-O-
glycoside, was shown to activate AMPK, resulting in down-regulated expression of 
PCSK9 in obese C57BL/6J mice.[129] 
 
3.6.10. Other extracts from natural products 
Apart from the abovementioned compounds, some crude extracts from natural products 
also demonstrated lipid-lowering effects by regulating PCSK9 directly or indirectly. An 
aqueous extract Phaleria macrocarpa (Scheff.) Boerl fruit was reported by Chong et al. 
to reduce cholesterol levels in vitro and in vivo.[130] Further mechanism studies 
showed that P. macrocarpa extract significantly upregulated both LDLR and PCSK9 
at the protein and mRNA levels, suggesting a mechanism that is similar to statin-
induced effects. Xuezhikang (XZK) is an extract from red yeast rice that contains a 
mixture of lovastatin, plant sterols, isoflavones, and other components. XZK is believed 
in China to be a useful nutraceutical for patients with cardiovascular disorders.[131] 
Recent studies demonstrated that XZK increased PCSK9 levels through the SREBP-2 
pathway,[132] which was similar to the mechanism behind the lipid-lowering effects 
of simvastatin.[133] In addition, some studies demonstrated that dietary n-3 
polyunsaturated fatty acids reduced plasma PCSK9 concentration and hepatic PCSK9 
mRNA expression, thereby exerting lipid-lowering effects.[134]         
 
4. Small-molecule PCSK9 inhibitors reported in patents 
The interface between PCSK9 and LDLR is extended, flat, and without deep binding 
pockets, which makes the interface a difficult target for small molecules. There is 
limited scientific literature reporting small molecules that directly inhibit the interaction 
between PCSK9 and LDLR; however, a few companies and institutions developed a 
series of small molecules targeting PCSK9/LDLR PPI, and some even disclosed the 
technical details.[135] In general, the strategies adopted by these companies targeting 
PCSK9/LDLR PPI are (a) altering the conformation of the protein PCSK9 through an 
allosteric mechanism and (b) targeting the “hot spots” of binding sites between PCSK9 
and LDLR. In addition, a considerable portion of the pharmaceutical company’s 
strategies focused on developing small molecules that inhibit PCSK9 expression at the 
genetic or protein levels. However, these small-molecule PCSK9 expression 
modulators might target other signal pathways and modulate PCSK9 expression 
indirectly, causing potential off-target effects. In addition, there are several patents that 
did not disclose the mechanism of their molecules. In this section, we will review the 
international patent publications reporting novel small molecules targeting PCSK9 for 
the treatment of CVDs. A brief summary of these patents is given in Table 2.  
 
4.1. Small molecules targeting the PCSK9/LDLR PPI 
Three patents, all from Portola Pharmaceuticals, disclosed that tetrahydroisoquinolines 
(44-46, WO 2017/034990 A1),[136] phenylalanines (47-49, WO 2017/034994 
A1),[137] and phenylpiperazines (50-52, WO 2017/034997 A1) [138] increased LDL-
uptake into liver cells, and LDLR cell surface populations (Figure 10). They declared 
that these compounds worked as ligands that directly bind the PCSK9 protein and 
differentially modify PCSK9 biological activity, changing the interactions between 
PCSK9 and LDLR. However, researchers of Portola have not reported any direct 
evidence in these patents that these small organic molecules bind PCSK9. 
 
 
Figure 10. Markush structures and representative compounds from Portola. (a): 
tetrahydroisoquinolines; (b) phenylalanines; (c) phenylpiperazine. 
 
Workers from the Shifa Biomedical Corporation have disclosed a series of 
compounds that modulate the physiological action of PCSK9, including its interaction 
with the LDLR. Various in vitro and in vivo assays have supported the biological 
activities of compounds claimed in three patents (WO 2014/150326 A1, WO 
2014/150395 A1, and WO 2017/222953 A1).[139-141] Some compounds inhibited the 
PCSK9/LDLR interaction, and the detailed data were disclosed in WO2017222953. 
The most potent benzofuran compound against the PCSK9/LDLR interaction was SBC-
115,337 (56), with an IC50 value of 0.5 μM (Figure 11). SBC-115,337 (56), SBC-
110,686 (57), SBC-110,733 (58), SBC-110,736 (59), SBC-110,034 (60), and SBC-
115,076 (61) were tested for their efficacy in male mice (C57BL/6 mice), and the data 
demonstrated that these compounds significantly lowered cholesterol levels (20%-
38%).  
Figure 11. Markush structures and representative compounds from Shifa. 
 
Many of the surfaces involved in the PPI are rather flat, making the development of 
small organic compounds to disrupt is difficult. However, most of the binding energy 
for the association of the two proteins is contributed by a few “hot spots” that can 
potentially be disrupted with small molecules. A group from Temple University 
disclosed a robust virtual screening method for the discovery of small molecules that 
bind PCSK9 and block its binding to the LDLR (Figure 12) (WO 2016/040305 
A1).[142] Approximately 1 million drug-like compounds and over 400k large 
compounds (MW>500) from ZINC databases were processed with screening 
campaigns, and eleven compounds were finally identified as lead hits. Coincidentally, 
some of these compounds have already been disclosed by the Shifa Biomedical 
Corporation. Further SAR studies and lead optimization based on the pyrazoles, 
represented by SBC-110,424 (62, Figure 12), and the 4-hydroxy-5-oxopyrroles, 
represented by SBC-115,076 (61), have been facilitated and accelerated by docking 
poses, but the results were not reported in detail in this patent. The detailed virtual 
screening process disclosed by Temple University for the development of small 
molecules blocking the PPI between PCSK9 and LDLR provided a reference to future 
research. 
 
Figure 12. Virtual screening method used to identify small molecules blocking the 
binding of PCSK9 to LDLR.  
 
In 2014, the SRX Cardio LLC described a set of synthetic peptides of 3-8 amino 
acids as allosteric inhibitors of PCSK9 (WO 2014/127316 A2).[143] These compounds 
were reported to bind and alter the conformation of the PCSK9 protein, changing the 
kinetics of the interaction between PCSK9 and LDLR. The most efficacious peptide is 
SRX55 (63, Figure 13a). Improved peptides were then designed by incorporating a 
negatively charged polar group to obtain better drug-like properties, and SRX60 (64), 
which contains a phosphate group, is a typical example. Two year later, the chemists 
from the SRX Cardio LLC simplified these peptides into small organic compounds, and 
negatively charged polar groups such as phosphate and tetrazole were retained (65-68, 
Figure 13b, WO 2016/029037 A1).[144] Considerable biological data were presented 
in this patent, including direct binding assays measured using backscatter 
interferometry. The most potent compound presented was SRX200 (66), which bound 
to recombinant human PCSK9 with a measured Kd of 24±8 nM. Allosteric modulation 
of PPI by small molecules binding to an allosteric site provides potential way forward 
for the difﬁcult targets without apparent deep pockets in the interface.[145] Developing 
allosteric inhibitors of PCSK9 which bind to the allosteric site of PCSK9 and alter the 
kinetics of the interaction between PCSK9 and LDLR seems to be a promising strategy 
identified by SRX Cardio LLC in this patent, which is worth following up.   
 
  
Figure 13. Representative compounds from SRX Cardio LLC. (a) Synthetic peptides; 
(b) Small organic compounds simplified from peptides.  
 
4.2. Small molecules inhibiting PCSK9 expression 
Recently, inventors from Paris have observed that steady-state PCSK9 mRNA levels in 
mouse primary hepatocytes surprisingly decreased by more than 90% after 24 h of 
treatment with anticancer agents IBET-151 (69, 2.5 μM) and JQ1 (70, 2.0 μM) (Figure 
14a).[146] Interestingly, JQ1 and IBET-151 are potent, highly specific, competitive 
inhibitors of acetyl-lysine for the bromodomain and extraterminal (BET) family of 
bromodomains (BRDs). These results show that BRD inhibitors may represent a novel 
way to inhibit PCSK9 expression and hence reduce circulating LDL levels; however, 
the detailed mechanism of the invention was not disclosed.  
Figure 14. Small molecules inhibiting PCSK9 expression. (a) Structure of JQ-1 and 
IBET-151; (b) Markush structure and representative compounds of fatty acid niacin 
conjugates. 
 A set of novel fatty acid niacin conjugates (71) was disclosed by Catabasis 
Pharmaceuticals in 2013 for treating or preventing metabolic diseases by inhibiting the 
production or lowering the serum levels of PCSK9 protein (WO 2013/177536 A2).[147] 
Two years later, a more extensive patent presenting significant activities for two 
selected compounds (72 and 73, Figure 14b) was disclosed by the same company (WO 
2015/073901 A1).[148] The surprising benefit of these N-alkylated fatty acid niacin 
conjugates is their ability to preferentially accumulate in the liver rather than other 
tissues. In 2016, the biological data supporting this result appeared in the scientific 
literature.[149] The fatty acid niacin conjugate 72 has been advanced into clinical trials 
to evaluate its effect on various lipid parameters. 
Chengdu Bestchiralbio Pharmaceuticals has also patented a set of substituted 
nitrogen-containing heterocyclic derivatives as inhibitors of PCSK9 that down regulate 
PCSK9 expression at the mRNA level. At least 166 analogs are exemplified in WO 
2016/107603 A1, and at least 87 analogs are exemplified in WO 2016/107602 A1.[150, 
151] Most of the compounds in these series have a substituted piperazine or piperidine 
ring. Figure 15a shows the in vivo assays of typical potent compounds in these two 
patents (74, 75). In addition, these compounds activated AMPK and can be used to treat 
type 2 diabetes.  
Figure 15. Representative compounds from (a) Chengdu Bestchiralbio; (b) Broad 
Institute; (c) Amorchem Holdings. 
 The Broad Institute described small molecules that modulate hepatic cholesterol by 
downregulating the expression levels of PCSK9 (inhibit the expression of PCSK9 
mRNA and secretion of PCSK9 protein) and upregulating the expression level of 
Tribbles homolog 1 (TRIB1) (WO 2014/028946 A2, and WO 2016/100711 A1).[152, 
153] The general formula (76, Figure 15b) is exemplified in 148 explicit examples. 
Compound 77 is the reference compound representing the series and was found to 
downregulate PCSK9 with an EC50 of 0.36 μM, as monitored by quantitative 
polymerase chain reaction (qPCR) analysis. 
At least 91 aminoacid-based compounds have been disclosed by a worker from 
AmorChem Holdings Inc., for preventing or treating LDL-C-related disease (WO 
2014/139008 A1).[154] Compounds of the invention were screened using biological 
PCSK9-based assays, and at least 24 compounds were identified to inhibit PCSK9 
secretion in a dose-dependent manner. Compounds 78-80 were typical examples 
(Figure 15c). However, the toxicity of some examples containing boric acid demands 
attention due to the potential carcinogenicity.[155] 
 
4.3. Additional patents 
Since 2011, Cadila Healthcare Pharmaceuticals have continuously published five 
patents (WO 2011/051961 A1, WO 2012/090220 A1, WO 2013/132509 A1, WO 
2014/002105 A1, and WO 2014/002106 A1) claiming compounds for the treatment of 
dyslipidemia and related diseases. The initial Markush structure in these patents is 
extremely broad, but all of the compounds contain a substituted tetrahydropyran moiety. 
Although a PCSK9/LDLR in vitro binding assay was performed to support the claimed 
formulas, the mechanism that is responsible for the hypocholesterolemic effect of these 
compounds has not yet been fully clarified in all these patents.[156-160]  
In 2018, researchers from Merck disclosed PCSK9 allosteric binding compounds 
bearing tetrahydroisoquinoline moiety (81, Figure 16).[161] These PCSK9 allosteric 
binders capable of stabilizing PCSK9 may stabilize PCSK9 in an inactive conformation, 
a conformation that inhibits PCSK9’s ability to bind to the LDLR, increasing the cell 
surface function of LDLR. In addition, some compounds in this invention exhibit the 
ability to lower steady state concentrations of both the pro and mature forms of PCSK9. 
For example, compound 82 was found to degrade mature PCSK9 level with DC50 value 
of 1.05 μM. Interestingly, some PCSK9 allosteric binders specifically bind PCSK9 at a 
unique site that does not interfere with the binding of PCSK9 with the LDLR, can be 
used, inter alia, in the detection, quantitation and imaging of PCSK9 in a sample when 
coupled with a detectable marker, e.g. a fluorescence probe or biotin (83, 84). These 
PCSK9 allosteric binding compounds disclosed by Merck have different functions 
when binding to PCSK9 at different allosteric sites, extending the capability of 
allosteric modulators. However, no further information about these allosteric sites was 
disclosed in this patent. 
 
Figure 16. Markush structure of PCSK9 allosteric binders and representative labeling 
probes from Merck. 
 
It is noteworthy that some compounds protected in patents have been reported in 
scientific journals and have been discussed in the first section of this review 
(WO2018/054959 A1, WO2018/053517 A1, WO2016/108572 A2, WO2014/170786 
A1, WO2016/055901 A1, and WO2014/005224 A1). Finally, it is difficult to obtain a 
comprehensive view of all small-molecule PCSK9 inhibitors reported in non-English 
patents due to language barriers (WO 2016/021706 A1, WO 2014/017569 A1, and WO 
2013/137371 A1); thus, other patents related to molecules that target PCSK9 might 
exist.  
 
Table 2  
Selected international patent applications related to small-molecule inhibitors of 
PCSK9. 
NO. Title Mechanism Publication 
number 
Publication 
date 
Applicant(s) 
1 Methods of inhibiting PCSK9 Not provided WO2018/129205 A1 12-07-2018 The Trustees of 
Dartmouth College 
2 Compounds for treatment of 
lipoprotein metabolism disorders 
Heparin analogues 
prevent PCSK9/LDLR 
complex formation 
WO2018/054959 A1 29-03-2018 AARHUS Universitet 
3 Substituted 1-methyl-1,2,3,4-
tetrahydroisoquiniline molecules as 
PCSK9 allosteric binders 
PCSK9 allosteric 
binding compounds 
WO2018/057409 A1 29-03-2018 Merck Sharp & Dohme 
Corp. 
4 Inhibitors of LDLR-PCSK9 protein-
protein interaction and methods of 
their use 
Disrupt the PPI 
between PCSK9 and 
LDLR 
WO2018/053517 A1 22-03-2018 The Texas A&M 
University 
5 Methods and compositions for 
reducing PCSK9 expression 
Inhibit PCSK9 
expression 
WO2018/024878 A1 08-02-2018 Centre National de la 
Recherche 
Scientifique (CNRS); 
Institut National de la 
Santé et de la 
Recherche Médicale 
(INSERM); 
Université Paris 
Descartes 
6 Antiproprotein convertase subtilisin 
kexin type 9 (anti-PCSK9) 
compounds and methods of using the 
same in the treatment and/or 
prevention of cardiovascular diseases 
Modulate the 
physiological action of 
PCSK9, including its 
interaction with the 
LDLR  
WO2017/222953 A1 28-12-2017 Shifa Biomedical 
Corporation 
7 Phenyl [a]indole[2,3-g]quinolizine 
compounds, preparation method 
therefor, pharmaceutical 
composition, and applications thereof 
Not provided WO2017/167202 A1 29-03-2017 Shanghai Institute of 
Materia Medica, 
Chinese Academy of 
Sciences 
8 Phenylpiperazine proprotein 
convertase subtilisin/kexin type 9 
(PCSK9) modulators and their use 
Bind to PCSK9 and 
alter the conformation 
of the protein 
WO2017/034997 A1 02-03-2017 Portola 
Pharmaceuticals, Inc. 
9 Composition and methods of use of 
tetrahydroisoquinoline small 
molecules to bind and modulate 
PCSK9 protein activity 
Bind to PCSK9 and 
alter the conformation 
of the protein 
WO2017/034990 A1 02-03-2017 Portola 
Pharmaceuticals, Inc. 
10 Composition and methods of use of 
novel phenylalanine small organic 
compounds to directly modulate 
PCSK9 protein activity 
Bind to PCSK9 and 
alter the conformation 
of the protein 
WO2017/034994 A1 02-03-2017 Portola 
Pharmaceuticals, Inc. 
11 Composition for preventing and 
treating cholesterol-related diseases 
Inhibit the linkage 
between PCSK9 and 
LDLR 
WO2016/108572 A2 07-07-2016 Industry-ACA-Demic 
Cooperation 
Foundation 
Yonsei University 
12 Substituted nitrogen-containing 
heterocyclic derivatives and 
applications thereof 
Inhibit PCSK9 
expression 
WO2016/107603 A1 07-07-2016 Chengdu Bestchiralbio 
LLC. 
13 Substituted nitrogen heterocyclic 
derivatives and use thereof 
Inhibit PCSK9 
expression 
WO2016/107602 A1 07-07-2016 Chengdu Bestchiralbio 
LLC. 
14 Modulators of hepatic lipoprotein 
metabolism 
Inhibit the expression 
of PCSK9 mRNA and 
secretion of PCSK9 
protein 
WO2016/100711 A1 23-06-2016 The Broad Institute, 
Inc. 
15 Substituted amide compounds Inhibit PCSK9 
translation 
WO2016/055901 A1 14-04-2016 Pfizer Inc. 
16 PCSK9 inhibitors and methods of use 
thereof  
Disrupt the PPI 
between PCSK9 and 
LDLR 
WO2016/040305 A1 17-03-2016 Temple University-of 
the Commonwealth 
System of Higher 
Education 
17 Composition and methods of use of 
small molecules as binding ligands 
for the modulation of proprotein 
convertase subtilisin/kexin type 9 
(PCSK9) protein activity 
Alter the conformation 
of the protein PCSK9 
WO2016/029037 A1 25-02-2016 SRX Cardio, LLC 
18 Fatty acid niacin conjugates Inhibit PCSK9 
expression and/or 
production 
WO2015/073901 A1 21-05-2015 Catabasis 
Pharmaceuticals, Inc. 
19 N-piperidin-3-ylbenzamide 
derivatives for treating 
cardiovascular diseases 
Inhibit the translation 
of PCSK9 mRNA to 
protein 
WO2014/170786 A1 23-10-2014 Pfizer Inc. 
20 Small molecule modulators of 
PCSK9 and methods of use thereof 
Inhibit PCSK9 
secretion 
 
WO2014/139008 A1 18-09-2014 Adaerata Limited 
Partnership; 
AmorChem Holdings 
Inc. 
21 Antiproprotein convertase subtilisin 
kexin type 9 (anti-PCSK9) 
Modulate the 
physiological action of 
WO2014/150326 A1 25-09-2014 Shifa Biomedical 
Corporation 
compounds and methods of using the 
same in the treatment and/or 
prevention of cardiovascular diseases 
PCSK9, including its 
interaction with the 
LDLR 
22 Anti-PCSK9 compounds and 
methods for the treatment and/or 
prevention of cardiovascular diseases 
Modulate the 
physiological action of 
PCSK9, including its 
interaction with the 
LDLR 
WO2014/150395 A1 25-09-2014 Shifa Biomedical 
Corporation 
23 Proprotein convertase 
subtilisin/kexin type 9 (PCSK9) 
allosteric binding ligands to modulate 
serum low density lipoprotein (LDL) 
levels 
Alter the conformation 
of the protein PCSK9 
WO2014/127316 A2 21-08-2014 SRX Cardio, LLC 
24 Modulators of hepatic lipoprotein 
metabolism 
Inhibit the expression 
of PCSK9 mRNA and 
secretion of PCSK9 
protein 
WO2014/028946 A2 20-02-2014 The Broad Institute, 
INC. 
25 Quercetin-3-glucoside and uses 
thereof 
Increase the amount of 
PCSK9 secreted by 
hepatocyte cells 
WO2014/005224 A1 09-01-2014 Mbikay Majambu 
Sirois Francine 
Chretien Michel 
Mayne Janice 
26 Novel compounds for the treatment 
of dyslipidemia and related diseases 
Not provided WO2014/002106 A1 03-01-2014 Cadila Healthcare 
Limited 
27 Compounds for the treatment of 
dyslipidemia and other diseases 
Not provided WO2014/002105 A1 03-01-2014 Cadila Healthcare 
Limited 
28 Novel compounds for the treatment 
of dyslipidemia and related diseases 
Not provided WO2013/132509 A1 12-03-2013 Cadila Healthcare 
Limited 
29 Methods of lowering proprotein 
convertase subtilisin/kexin types 
(PCSK9) 
Inhibit the production 
of PCSK9 
WO2013/177536 A2 28-11-2013 Catabasis 
Pharmaceuticals, INC. 
30 Heterocyclic compounds suitable for 
the treatment of dyslipidemia 
Not provided WO2012/090220 A1 05-07-2012 Cadila Healthcare 
Limited 
31 Compounds for the treatment of 
dyslipidemia and related diseases 
Not provided WO2011/051961 A1 05-05-2011 Cadila Healthcare 
Limited 
32 Berberine derivatives useful for 
modulating lipid levels and their 
methods of synthesis 
Inhibit PCSK9 
expression 
WO2011/006000 A1 13-01-2011 Liu Haiyan 
Li Gaoping 
Wang Junbo 
Liu Jingwen 
33 Corydaline derivatives useful for 
reducing lipid levels 
Inhibit PCSK9 
expression 
WO2010/075469 A1 01-07-2010 CVI Pharmaceuticals 
Limited 
 
5. Potential strategies for the design of small molecules  
The search is on to develop small-molecule inhibitors of PCSK9, and some potential 
strategies or techniques that might be applied to the design of novel small-molecule 
PCSK9 inhibitors will be introduced in this section.  
 
5.1. Another binding site on PCSK9 for the design of small-molecule inhibitors 
The abovementioned characteristics of PCSK9 implied that developing small-molecule 
inhibitors based on the EGF(A)-binding site is difficult. Altering the conformation of 
PCSK9 by allosteric inhibitors has been successfully displayed by SRX Cardio LLC, 
but the relevant patents did not uncover the allosteric site. A recent study from the 
Kirchhofer group discovered a cryptic peptide-binding site next to the LDLR-binding 
site on PCSK9, which is possible for small molecules to target this site and inhibit 
LDLR binding by a steric mechanism.[162] The findings suggested that the P’-helix 
(Ser153-Thr162 of the catalytic domain) is intrinsically labile and adopts different 
conformational states; in the ‘out’ state, the groove becomes accessible for peptides to 
bind, which could antagonize LDLR binding by a steric mechanism. Grooved-binding 
antagonistic peptides that share sequence homology with the native P’-helix are potent 
PCSK9 inhibitors, affording a new strategy for the development of small molecules 
from these peptides to antagonize PCSK9.[163] 
 
5.2. Aptamers 
Aptamers are synthetic oligonucleotides or peptides that bind to a specific target 
molecule with high affinity. Aptamers are now used ubiquitously as binding agents for 
a broad range of applications.[164] They function similarly to mAbs, but have more 
advantages over antibodies. The fact that unmodified DNA or RNA aptamers have less 
chemical diversity than antibodies limits their wide application. Recently, a group from 
SomaLogic, Inc. reported the selection and identification of DNA aptamers in which 
one or both pyrimidines were replaced by side-chain-functionalized variants that bind 
and inhibit PCSK9 with dissociation constants similar to those of approved antibodies 
(evolocumab, KD = 8.0 pM, and alirocumab, KD = 0.58 nM).[165] Recently, Liu and 
co-workers developed a ligase-mediated DNA-templated polymerization and in vitro 
selection system, and diverse highly functionalized nucleic acid polymers (HFNAPS) 
were prepared. HFNAPs that bind PCSK9 were selected for further diversification and 
reselection, resulting in an improved PCSK9-binding HFNAP with a KD of 3 nM, which 
potently inhibited the binding between PCSK9 and the LDLR. These studies shed light 
on designing extensively chemically functionalized aptamers as potential PCSK9 
inhibitors.[166]  
 
5.3. Proteolysis-targeting chimera technology 
It seems from the current data that low PCSK9 function and LDL-C levels caused by 
PCSK9 inhibitors or LOF mutations did not trigger possible deleterious effects.[167] 
An extreme example comes from a patient who was a compound heterozygote for the 
Y142X and ΔR97 LOF mutations, which disrupt the synthesis and processing/secretion 
of PCSK9, respectively. No additional adverse events were observed in this patient, 
although the levels of PCSK9 were below the limit of detection and the LDL-C level 
was as low as 14 mg/dL.[167] RNA interference, antisense RNA and CRISPR-Cas9 
techniques are often used to knock down the target protein, but proteolysis-targeting 
chimera (PROTAC) technology has recently been successfully applied to selective 
degradation of multiple protein targets other than PCSK9.[168] PROTAC methods 
utilize endogenous cellular quality control machinery by recruiting it to the target 
protein to induce its degradation. Thus, the targeted degradation of PCSK9 protein 
using PROTAC technology might be possible, although there have been no related 
reports in the literature.   
 
5.4. Targeting the signal transduction cascade 
Relatively little is known about the PCSK9 promoter. PCSK9 and LDLR are 
coregulated by SREBP-2.[169] Reducing the amount of PCSK9 mRNA by disrupting 
the SREBP pathway would be expected to down-regulate transcription of the LDLR 
gene, which would counteract a beneficial effect of lowering PCSK9 levels. The Kowa 
Company reported a new cholesteryl ester transfer protein (CETP) inhibitor, K-312, 
that suppressed PCSK9 expression through modulation of its transcription by 
decreasing SREBP levels, representing a novel strategy to reduce LDL-C.[170] Thus, 
with the development of the molecular biology of PCSK9, more signaling pathways 
and interconnected factors of PCSK9 will be unveiled and facilitate the search for new 
inhibitors of PCSK9 activity.[171] Several natural products have been widely reported 
to modulated PCSK9 levels without detailed mechanisms, and mechanism studies 
about these natural products may facilitate reveling the signaling pathways associated 
with PCSK9. 
 
6. Summary and future directions 
The cost of current PCSK9-blocking antibodies ($US14,500 and $US14,100 per year 
for evolocumab and alirocumab, respectively) has aroused a fierce debate, as only 15% 
relative risk reduction resulted from these expensive antibodies.[172] The cost-
effectiveness ratio may be acceptable for patients currently with familial 
hypercholesterolemia, but for patients with conventional vascular disease, these 
antibodies are not so cost effective.[173, 174] The appeal of small-molecule inhibitors 
of PCSK9 over antibodies is rather clear, because you can achieve the same goal with 
only hundreds of dollars, let alone the potential for delivering the inhibitors via oral 
pills instead of injectable antibodies. In addition, despite antibodies perturbing the 
binding of PCSK9 to LDLR, by their nature, anti-PCSK9 mAbs are unable to modulate 
PCSK9 and LDL-C levels in an intermediate fashion, while the inhibition of PCSK9 
synthesis by a small molecule could provide additional options for patients and 
physicians by offering different levels of inhibition to balance safety and efficacy. Thus, 
orally administrated small molecule is a preferred approach to inhibit PCSK9. 
Base on the above descriptions, three strategies can be concluded that have been 
applied to inhibit PCSK9 with small molecules, including 1) preventing the binding of 
PCSK9 to LDLR; 2) interfering with the maturation and secretion processing or the 
biological function of PCSK9; and 3) inhibiting the synthesis and expression of PCSK9. 
Designing small molecules disrupting the PPI between PCSK9 and the LDLR is the 
most immediate strategy but also the toughest way to discover small-molecule PCSK9 
inhibitors. The KD for PCSK9/LDLR is in submicromolar level,[175] which makes 
small-molecule inhibitors targeting the relatively flat EGF(A)-binding site on PCSK9 
quite challenging. The discovery of “hot spots” makes it possible to prevent the binding 
of PCSK9 to the LDLR directly; in addition, altering the conformation of PCSK9 
(allosteric modulators) can also change the interactions between PCSK9 and LDLR, 
leading to reduced levels of circulating LDL-C.[176] However, considering the potent 
binding affinity between PCSK9 and LDLR, most of the currently reported inhibitors 
targeting the PPI between PCSK9 and LDLR directly may not be potent enough to 
disrupt the binding. Altering the conformation of PCSK9 by allosteric inhibitors or 
targeting the newly found adjacent P’-helix site may offer more hope for disrupting the 
PCSK9/LDLR interaction with small molecules in the future. Maturation and secretion 
processing are required for PCSK9 function, and a small-molecule inhibitor that 
interferes with these processes would block, suppress, and reduce PCSK9 biological 
activity or decrease the amount of mature, secreted PCSK9. However, few small-
molecule inhibitors have been reported that reduce LDL-C levels through this pathway. 
Transcription and translation of PCSK9 are controlled by many factors, and a small 
molecule targeting these factors would also reduce the synthesis and expression of 
PCSK9 protein. Many small-molecule inhibitors, like natural products, have been 
reported to reduce PCSK9 at the gene or protein levels, but their detailed mechanisms 
need further study. Cell-based HTS afforded opportunities to overtake PPI-based 
strategies. In addition, mechanism of action studies of compounds from HTS or natural 
products might disclose novel mechanisms and facilitate the discovery of small-
molecule PCSK9 inhibitors.    
Up to date, antibody targeting mature PCSK9 is the most advanced modality, other 
points of intervention and modalities have also been widely reported. In all cases, small 
molecule progress has lagged behind. Although researchers have dabbled with the 
discovery of PCSK9 inhibitors, no significant progress toward small-molecule PCSK9 
inhibitors has been made up to date. In recent five years, great efforts have been made 
to develop small-molecular PCSK9 inhibitors. This review, which highlights a few of 
the recent advances in small-molecule PCSK9 inhibitors, is a witness to the growing 
interest for and importance of this field. A pill that inhibits PCSK9 is "a Holy Grail" in 
the world of lowering LDL-C, and many companies and institutions are struggling to 
commercialize the first PCSK9 small-molecular inhibitors and win the chance to build 
a franchise in what is expected to be a blockbuster. Nevertheless, "a Holy Grail" is still 
at the top of the mountain, waiting for anyone who is keen and ambitious enough to 
pluck it.  
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